Cell separation matrix

• US 20020164825A1
• Filed: 04/11/2002
• Published: 11/07/2002
• Est. Priority Date: 09/09/2000
• Status: Abandoned Application

• Current Assignee: Wen-Tien Chen
• Original Assignee: Wen-Tien Chen
• Inventors: Chen, Wen-Tien
• Application Number:
  US10/122,268
• Publication Number:
  US 20020164825A1
• Time in Patent Office: Days
• US Class Current: 436/526
• CPC Class Codes: G01N 33/56966 Animal cells
• CPC Class Codes: G01N 33/574 for cancer
• CPC Class Codes: G01N 33/57488 involving compounds identifable in body fluids

Abstract

A novel modified matrix system, mimicking a metastatic environment, that can be used to capture and detect viable cancer and normal cells from tissue fluid samples derived from cancer subjects and which provides effective cell separation for diagnostic and therapeutic applications in treating patients with metastatic diseases.

Claims

1. A matrix for detecting the presence of cancer cells in a subject, said matrix comprising a solid core material bearing a coating having binding affinity for said solid core material and binding affinity for blood-borne adhesion components that bind cancer cells, and one or more blood-borne adhesion components.

2. The matrix of claim 1 wherein said blood-borne adhesion component is selected from the plasma group consisting of:

fibronectin, fibrin, heparin, laminin, tenascin, vitronectin, and biologically functional mimics of the same.

3. The matrix of claim 1 wherein said solid core material is selected from the group consisting of:

bone, connective tissue, collagens, gelatin, hyaluronates, fibrin, cotton, wool, polymeric material, polystyrene, magnetic colloid, glass, polyamides, polyesters, cellulose acetate, urethane, DEAE-dextran, dacron, rayon, and acrylate.

4. The matrix of claim 1 wherein said coating comprises an attachment agent having a binding affinity for at least one of the blood-borne adhesion components.

5. The matrix of claim 1 wherein said coating is selected from the group consisting of:

gelatin, glutaraldehyde, and gelatin crosslinked with glutaraldehyde;

11. The cell separation system of claim 6 wherein matrix of claim 1 wherein said one or more natural or synthetic molecules having a binding affinity for metastatic cancer cells is selected from the plasma group consisting of:

fibronectin, fibrin, heparin, laminin, tenascin, vitronectin, and biologically functional mimics of the same.

13. The cell separation system of claim 12 wherein said sealable container is a collection tube.

14. The cell separation system of claim 13 wherein said adhesion binding material comprises an attachment agent having a binding affinity for at least one of the blood-borne adhesion components.

15. The cell separation system of claim 13 wherein said adhesion binding material is selected from the group consisting of:

gelatin, glutaraldehyde, and gelatin crosslinked with glutaraldehyde.

16. The cell separation system of claim 12 wherein said adhesion binding material further comprises a core material selected from the group consisting of:

bone, connective tissue, collagens, gelatin, hyaluronates, fibrin, cotton, wool, polymeric material, polystyrene, magnetic colloid, glass, polyamides, polyesters, cellulose acetate, urethane, DEAE-dextran, dacron, rayon, and acrylate.

17. The cell separation system of claim 12 wherein said one or more natural or synthetic molecules having a binding affinity for metastatic cancer cells is selected from the plasma group consisting of:

fibronectin, fibrin, heparin, laminin, tenascin, vitronectin, and biologically functional mimics of the same.

18. The cell separation system of claim 12 wherein said cell separation member is a screen.

19. The cell separation system of claim 12 wherein said cell separation member is a filter.

6. A metastatic cancer cell separation system comprising:

a sealable container having an outer surface and an inner surface;

an adhesion binding material coated on said inner surface of said sealable container, said adhesion binding material having the ability to bind said inner surface of said sealable container and the ability to bind one or more natural or synthetic molecules that have a binding affinity for metastatic cancer cells; and

one or more natural or synthetic molecules having a binding affinity for metastatic cancer cells.

7. The cell separation system of claim 6 wherein said sealable container is a collection tube.

8. The cell separation system of claim 6 wherein said adhesion binding material comprises an attachment agent having a binding affinity for at least one of the blood-borne adhesion components.

9. The cell separation system of claim 6 wherein said adhesion binding material is selected from the group consisting of:

gelatin, glutaraldehyde, and gelatin crosslinked with glutaraldehyde.

10. The cell separation system of claim 6 wherein said adhesion binding material further comprises a core material selected from the group consisting of:

bone, connective tissue, collagens, gelatin, hyaluronates, fibrin, cotton, wool, polymeric material, polystyrene, magnetic colloid, glass, polyamides, polyesters, cellulose acetate, urethane, DEAE-dextran, dacron, rayon, and acrylate.

12. A metastatic cancer cell separation system comprising:

a sealable container having an outer surface and an inner surface, said inner surface defining a void;

a plurality of beads coated with an adhesion binding material bound to one or more natural or synthetic molecules that have a binding affinity for metastatic cancer cells, said beads residing within said void;

a separation member positioned in said void in such a manner as to divide said void into two or more compartments said filter having pores of a size to permit filtration of said beads.

20. A metastatic cancer cell separation system comprising:

a sealable container having an outer surface and an inner surface, said inner surface defining a void;

a plurality of magnetically-attractable microbeads or nanoparticles coated with an adhesion binding material bound to one or more natural or synthetic molecules that have a binding affinity for metastatic cancer cells, said microbeads or nanoparticles residing within said void; and

a magnet on the outer surface of said sealable container, or within said void, of sufficient strength to attract said plurality of magnetic-attractable microbeads or nanoparticles to one location.

21. The cell separation system of claim 20 wherein said sealable container is a collection tube.

22. The cell separation system of claim 20 wherein said sealable container is a flow chamber.

23. The cell separation system of claim 20 wherein said adhesion binding material comprises an attachment agent having a binding affinity for at least one of the blood-borne adhesion components.

24. The cell separation system of claim 20 wherein said adhesion binding material is selected from the group consisting of:

gelatin, glutaraldehyde, and gelatin crosslinked with glutaraldehyde.

25. The cell separation system of claim 20 wherein said adhesion binding material further comprises a magnetic colloid intermediate layer in the core material selected from the group consisting of:

bone, connective tissue, collagens, gelatin, hyaluronates, fibrin, cotton, wool, polymeric material, polystyrene, glass, polyamides, polyesters, cellulose acetate, urethane, DEAE-dextran, dacron, rayon, and acrylate.

26. The cell separation system of claim 20 wherein said one or more natural or synthetic molecules having a binding affinity for metastatic cancer cells is selected from the plasma group consisting of:

fibronectin, fibrin, heparin, laminin, tenascin, vitronectin, and biologically functional mimics of the same.

28. The cell separation system of claim 27 wherein said adhesion binding material comprises an attachment agent having a binding affinity for at least one of the blood-borne adhesion components.

29. The cell separation system of claim 27 wherein said adhesion binding material is selected from the group consisting of:

gelatin, glutaraldehyde, and gelatin crosslinked with glutaraldehyde.

30. The cell separation system of claim 27 wherein said adhesion binding material further comprises a core material selected from the group consisting of:

bone, connective tissue, collagens, gelatin, hyaluronates, fibrin, cotton, wool, polymeric material, polystyrene, magnetic colloid, glass, polyamides, polyesters, cellulose acetate, urethane, DEAE-dextran, dacron, rayon, and acrylate.

31. The cell separation system of claim 27 wherein said one or more natural or synthetic molecules having a binding affinity for metastatic cancer cells is selected from the plasma group consisting of:

fibronectin, fibrin, heparin, laminin, tenascin, vitronectin, and biologically functional mimics of the same.

32. The cell separation system of claim 27 wherein said cell separation member is a screen.

33. The cell separation system of claim 27 wherein said cell separation member is a filter.

34. The cell separation system of claim 27 wherein said cell separation beads form the filter unit.

27. A metastatic cancer cell separation system comprising:

an enclosed container defining a void, said enclosed container having an inlet and an outlet;

a first separation member positioned proximal to said inlet within said void and dividing said void into compartments, said first separation member permitting the flow of at least a component of whole blood therethrough;

a second separation member positioned proximal to said outlet within said void and dividing said void into compartments, said second separation member permitting the flow of at least a component of whole blood therethrough and being positioned antepodal to said first separation member in said void;

a plurality of beads coated with an adhesion binding material bound to one or more natural or synthetic molecules that have a binding affinity for metastatic cancer cells, said beads residing between said first separation member and second separation member and being retained thereby within said void.